title: Adenosine amine congener mitigates noise-induced cochlear injury.
abstract: Hearing loss from noise exposure is a leading occupational disease, with up to 5% of the population at risk world-wide. Here, we present a novel purine-based pharmacological intervention that can ameliorate noise-induced cochlear injury. Wistar rats were exposed to narrow-band noise (8-12 kHz, 110 dB SPL, 2-24 h) to induce cochlear damage and permanent hearing loss. The selective adenosine A(1) receptor agonist, adenosine amine congener (ADAC), was administered intraperitoneally (100 microg/kg/day) at time intervals after noise exposure. Hearing thresholds were assessed using auditory brainstem responses and the hair cell loss was evaluated by quantitative histology. Free radical damage in the organ of Corti was assessed using nitrotyrosine immunohistochemistry. The treatment with ADAC after noise exposure led to a significantly greater recovery of hearing thresholds compared with controls. These results were upheld by increased survival of sensory hair cells and reduced nitrotyrosine immunoreactivity in ADAC-treated cochlea. We propose that ADAC could be a valuable treatment for noise-induced cochlear injury in instances of both acute and extended noise exposures.
authors.forename: Srdjan M
authors.initials: SM
authors.lastname: Vlajkovic
authors.forename: Kyu-Hyun
authors.initials: KH
authors.lastname: Lee
authors.forename: Ann Chi Yan
authors.initials: AC
authors.lastname: Wong
authors.forename: Cindy X
authors.initials: CX
authors.lastname: Guo
authors.forename: Rita
authors.initials: R
authors.lastname: Gupta
authors.forename: Gary D
authors.initials: GD
authors.lastname: Housley
authors.forename: Peter R
authors.initials: PR
authors.lastname: Thorne
references.citation: Clin Neurophysiol. 2004 May;115(5):1129-39
references.pmid: 15066538
references.citation: Ann N Y Acad Sci. 1999 Nov 28;884:233-48
references.pmid: 10842597
references.citation: J Neurosci. 2002 Oct 15;22(20):9122-33
references.pmid: 12388620
references.citation: Hear Res. 2007 Apr;226(1-2):22-43
references.pmid: 17141991
references.citation: Neuroscience. 2005;134(2):633-42
references.pmid: 15961244
references.citation: Ear Hear. 2006 Feb;27(1):1-19
references.pmid: 16446561
references.citation: Audiol Neurootol. 1999 Sep-Oct;4(5):229-36
references.pmid: 10436315
references.citation: Ann N Y Acad Sci. 1999 Nov 28;884:171-91
references.pmid: 10842593
references.citation: Eur J Pharmacol. 1999 Mar 26;369(3):313-7
references.pmid: 10225368
references.citation: Cell Tissue Res. 2007 Jun;328(3):461-71
references.pmid: 17285327
references.citation: Audiol Neurootol. 2006;11(6):343-56
references.pmid: 16988498
references.citation: Drug Discov Today. 2005 Oct 1;10(19):1291-8
references.pmid: 16214673
references.citation: J Biol Chem. 2000 Sep 29;275(39):30272-9
references.pmid: 10887176
references.citation: J Neurophysiol. 1999 Sep;82(3):1647-50
references.pmid: 10482781
references.citation: Brain Res. 2000 Sep 29;878(1-2):163-73
references.pmid: 10996147
references.citation: Neurosci Lett. 2005 Jun 3;380(3):234-8
references.pmid: 15862892
references.citation: Hear Res. 2005 Sep;207(1-2):35-42
references.pmid: 15935579
references.citation: Hear Res. 1997 Nov;113(1-2):198-206
references.pmid: 9387999
references.citation: Nat Rev Drug Discov. 2006 Mar;5(3):247-64
references.pmid: 16518376
references.citation: Hear Res. 1997 Mar;105(1-2):130-40
references.pmid: 9083810
references.citation: J Med Chem. 1985 Sep;28(9):1341-6
references.pmid: 2993623
references.citation: Brain Res. 2004 Sep 3;1019(1-2):201-9
references.pmid: 15306254
references.citation: Trends Pharmacol Sci. 1995 Sep;16(9):283-5
references.pmid: 7482990
references.citation: Eur J Pharmacol. 1996 Dec 5;316(2-3):171-9
references.pmid: 8982684
references.citation: Biochem Biophys Res Commun. 1994 Jun 15;201(2):508-15
references.pmid: 8002980
references.citation: Hear Res. 2003 May;179(1-2):21-32
references.pmid: 12742235
references.citation: Neurobiol Aging. 2007 Oct;28(10):1605-12
references.pmid: 16920227